These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38335394)

  • 41. SDF-1 expression and tumor-infiltrating lymphocytes identify clinical subtypes of triple-negative breast cancer with different responses to neoadjuvant chemotherapy and survival.
    Wang RX; Ji P; Gong Y; Shao ZM; Chen S
    Front Immunol; 2022; 13():940635. PubMed ID: 36341391
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinicopathological significance of the immunologic signature (PDL1, FOXP3+ Tregs, TILs) in early stage triple-negative breast cancer treated with neoadjuvant chemotherapy.
    Abdelrahman AE; Rashed HE; MostafaToam ; Omar A; Abdelhamid MI; Matar I
    Ann Diagn Pathol; 2021 Apr; 51():151676. PubMed ID: 33360026
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis.
    Gao G; Wang Z; Qu X; Zhang Z
    BMC Cancer; 2020 Mar; 20(1):179. PubMed ID: 32131780
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chemosensitivity, tumor infiltrating lymphocytes (TILs), and survival of postpartum PABC patients treated by neoadjuvant chemotherapy.
    Labrosse J; Abdennebi I; Thibault L; Laas E; Merckelbagh H; Morel C; Lam T; Lae M; Reyal F; Hamy AS
    Breast; 2018 Dec; 42():61-67. PubMed ID: 30179779
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer.
    Kurozumi S; Inoue K; Matsumoto H; Fujii T; Horiguchi J; Oyama T; Kurosumi M; Shirabe K
    Sci Rep; 2019 Feb; 9(1):1583. PubMed ID: 30733496
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Exploratory analysis of immune checkpoint receptor expression by circulating T cells and tumor specimens in patients receiving neo-adjuvant chemotherapy for operable breast cancer.
    Wesolowski R; Stiff A; Quiroga D; McQuinn C; Li Z; Nitta H; Savardekar H; Benner B; Ramaswamy B; Lustberg M; Layman RM; Macrae E; Kassem M; Williams N; Sardesai S; VanDeusen J; Stover D; Cherian M; Mace TA; Yu L; Duggan M; Carson WE
    BMC Cancer; 2020 May; 20(1):445. PubMed ID: 32429929
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Deep learning with biopsy whole slide images for pretreatment prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer：A multicenter study.
    Li B; Li F; Liu Z; Xu F; Ye G; Li W; Zhang Y; Zhu T; Shao L; Chen C; Sun C; Qiu B; Bu H; Wang K; Tian J
    Breast; 2022 Dec; 66():183-190. PubMed ID: 36308926
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tumor-infiltrating lymphocytes as a predictor of axillary and primary tumor pathological response after neoadjuvant chemotherapy in patients with breast cancer: a retrospective cohort study.
    Chin K; Landén AH; Kovács A; Wärnberg F; Ekholm M; Karlsson P; Olofsson Bagge R
    Breast Cancer Res Treat; 2024 Aug; 207(1):49-63. PubMed ID: 38703286
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intratumoral Tumor Infiltrating Lymphocytes (TILs) are Associated With Cell Proliferation and Better Survival But Not Always With Chemotherapy Response in Breast Cancer.
    Wu R; Oshi M; Asaoka M; Yan L; Benesch MGK; Khoury T; Nagahashi M; Miyoshi Y; Endo I; Ishikawa T; Takabe K
    Ann Surg; 2023 Oct; 278(4):587-597. PubMed ID: 37318852
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
    Hamy AS; Bonsang-Kitzis H; De Croze D; Laas E; Darrigues L; Topciu L; Menet E; Vincent-Salomon A; Lerebours F; Pierga JY; Brain E; Feron JG; Benchimol G; Lam GT; Laé M; Reyal F
    Clin Cancer Res; 2019 Nov; 25(22):6731-6741. PubMed ID: 31515462
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Association of tumor-infiltrating lymphocytes before and after neoadjuvant chemotherapy with pathological complete response and prognosis in patients with breast cancer.
    Hong J; Rui W; Fei X; Chen X; Shen K
    Cancer Med; 2021 Nov; 10(22):7921-7933. PubMed ID: 34562054
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tumor-infiltrating lymphocytes in breast cancer predict the response to chemotherapy and survival outcome: A meta-analysis.
    Wang K; Xu J; Zhang T; Xue D
    Oncotarget; 2016 Jul; 7(28):44288-44298. PubMed ID: 27329588
    [TBL] [Abstract][Full Text] [Related]  

  • 53. HER2-positive is an independent indicator for predicting pathological complete response to neoadjuvant therapy and Ki67-changed after neoadjuvant chemotherapy predicts favorable prognosis in Chinese women with locally advanced breast cancer.
    Fang Y; Zhang Q; Wu Y; Wu J
    Medicine (Baltimore); 2024 Feb; 103(6):e37170. PubMed ID: 38335419
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
    Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
    Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Locally advanced breast cancer: Tumor-infiltrating lymphocytes as a predictive factor of response to neoadjuvant chemotherapy.
    Russo L; Maltese A; Betancourt L; Romero G; Cialoni D; De la Fuente L; Gutierrez M; Ruiz A; Agüero E; Hernández S
    Eur J Surg Oncol; 2019 Jun; 45(6):963-968. PubMed ID: 30745134
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CD73 expression and pathologic response to neoadjuvant chemotherapy in triple negative breast cancer.
    Cerbelli B; Botticelli A; Pisano A; Pernazza A; Campagna D; De Luca A; Ascierto PA; Pignataro MG; Pelullo M; Rocca CD; Marchetti P; Fortunato L; Costarelli L; d'Amati G
    Virchows Arch; 2020 Apr; 476(4):569-576. PubMed ID: 31853625
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Estrogen Receptor Positive Breast Cancer with High Expression of Androgen Receptor has Less Cytolytic Activity and Worse Response to Neoadjuvant Chemotherapy but Better Survival.
    Okano M; Oshi M; Butash AL; Asaoka M; Katsuta E; Peng X; Qi Q; Yan L; Takabe K
    Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31151151
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis.
    Petrelli F; Coinu A; Borgonovo K; Cabiddu M; Ghilardi M; Lonati V; Barni S
    Breast Cancer Res Treat; 2014 Apr; 144(2):223-32. PubMed ID: 24557340
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
    Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
    Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic Significance of Stromal Versus Intratumoral Infiltrating Lymphocytes in Different Subtypes of Breast Cancer Treated With Cytotoxic Neoadjuvant Chemotherapy.
    Khoury T; Nagrale V; Opyrchal M; Peng X; Wang D; Yao S
    Appl Immunohistochem Mol Morphol; 2018 Sep; 26(8):523-532. PubMed ID: 28187033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.